Cipla
Focus: Cipla is a Mumbai-headquartered generics and API manufacturer specializing in infectious diseases, oncology, and respiratory therapeutics with a global portfolio of post-LOE branded generics. The company derives 33% of revenue from a single product (Darunavir), indicating a concentrated but established revenue base.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Cipla
AI assessmentNot HiringNo open roles listed right now. Follow Cipla to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Late-stage
6 Phase 3+
LOE Risk
1 imminent
ARGATROBAN IN SODIUM CHLORIDE
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$19M Part DDeclining
Post-LOE
Accounts for 33% of company revenue but faces inevitable generic competition erosion post-loss-of-exclusivity.
Help build intelligence for Cipla
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.